SCHEMBL1591271

SCHEMBL1591271

COc1cc2c(Oc3ccc(NS(=O)(=O)c4cccc(-c5ccccc5)c4)cc3F)ccnc2cc1OCCCN1CCCC(C)C1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 12/20 0.76
MET P08581 11/20 0.75
EGFR P00533 10/20 0.75
SRC P12931 3/20 0.75
INSR P06213 3/20 0.70
TBKBP1 A7MCY6 1/20 0.63
PLK4 O00444 1/20 0.63
AURKA O14965 1/20 0.63
GAK O14976 1/20 0.63
RIPK2 O43353 1/20 0.63
PRKAB2 O43741 1/20 0.63
ERN1 O75460 1/20 0.63
STK10 O94804 1/20 0.63
FYN P06241 1/20 0.63
YES1 P07947 1/20 0.63
LYN P07948 1/20 0.63
FER P16591 1/20 0.63
MARK3 P27448 1/20 0.63
ECHS1 P30084 1/20 0.63
MAP2K2 P36507 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1546671 0.95 AXL (0.81) AXLMETEGFRSRCINSR
SCHEMBL1546627 0.93 AXL (0.75) AXLMETEGFRSRCINSR
SCHEMBL1547357 0.93 AXL (0.82) AXLMETEGFRSRCINSR
SCHEMBL1546678 0.92 AXL (0.77) AXLMETEGFRSRCINSR
SCHEMBL1546618 0.92 AXL (0.77) AXLMETEGFRSRCINSR
SCHEMBL1591631 0.92 AXL (0.77) AXLMETEGFRSRCINSR
SCHEMBL12708866 0.92 AXL (0.76) AXLMETEGFRSRCINSR
SCHEMBL1546691 0.92 AXL (0.78) AXLMETEGFRSRCINSR
SCHEMBL12709196 0.92 AXL (0.80) AXLMETEGFRSRCINSR
SCHEMBL1547412 0.91 AXL (0.80) AXLMETEGFRSRCINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206130-B2 Quinoline derivatives as AXL kinase inhibitors MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-12-08 US disclosed
US-9206130-B2 Quinoline derivatives as AXL kinase inhibitors MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-12-08 US disclosed
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 US disclosed
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 US disclosed
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS AXL, FLT3, TYRO3 AXL 1/4885MET 71/4885EGFR 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.